Statins news from FiercePharma
NewsMake generic-switching bonuses illegal?
Should insurers be allowed to reward docs who switch patients to generics? That debate is going public in Colorado, where legislators have proposed a bill that would prohibit the practice. On the Read more...
FDA shoots down Mevacor OTC
It's official: Merck's off-patent statin drug Mevacor can't go over-the-counter. About a month after Read more...
Insurers pay docs for generic-switching
Maybe the folks probing drug company payments to docs should expand their field a bit. Now, health plans are drawing scrutiny for paying physicians to prescribe cheaper generics rather than Read more...
Heart docs back Vytorin
Day three of chatter about Vytorin's poor performance in the ENHANCE study, and the furor seems to be Read more...
Merck, Schering's Vytorin fails trial
The gig is up, the news is out. Merck and Schering-Plough announced the results of its big ENHANCE trial this morning. And, as observers had begun to suspect, the study showed that, when it comes to Read more...
SPOTLIGHT: Study: Diabetics should take statins
For the second time this week, statins are being trumpeted for a new population. This time, it's diabetics who Read more...
Study: Statins cut cancer by 25%
It's potential manna from heaven for statin makers: A new study shows the drugs may prevent cancer. Real FDA-sanctioned marketing is years of research away, but we expect a flurry of journal article Read more...
Schering CEO defends Vytorin decisions
Talk about the hot seat. At a Morgan Stanely pharma conference yesterday, Schering-Plough CEO Fred Hassan (photo) was Read more...
Novartis CEO's statin? Pfizer's Lipitor
What's a pharma CEO with high cholesterol to do? Take his company's statin, of course. But Novartis chief Daniel Vasella (Read more...
| Press ReleasesPRESS RELEASE: FDA Advisory Panel Recommends Against Approval of Merck's NDA for Non-prescription MEVACOR FDA Advisory Panel Recommends Against Approval of Merck's NDA for Non-prescription MEVACOR® (lovastatin) 20 mg WHITEHOUSE STATION, N.J., Dec. 13, 2007 - Merck & Co., Inc. announced today that Read more... |
Get more Statins coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight